Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to -$15000.0.

  • Niagen Bioscience's Gains from Investment Securities rose 2857.14% to -$15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$59000.0, marking a year-over-year increase of 2337.66%. This contributed to the annual value of -$80000.0 for FY2024, which is 666.67% down from last year.
  • Niagen Bioscience's Gains from Investment Securities amounted to -$15000.0 in Q3 2025, which was up 2857.14% from -$13000.0 recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Gains from Investment Securities registered a high of -$13000.0 during Q4 2022, and its lowest value of -$30000.0 during Q3 2021.
  • For the 5-year period, Niagen Bioscience's Gains from Investment Securities averaged around -$19526.3, with its median value being -$20000.0 (2022).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 15454.55% in 2021, then soared by 4482.76% in 2022.
  • Quarter analysis of 5 years shows Niagen Bioscience's Gains from Investment Securities stood at -$21000.0 in 2021, then skyrocketed by 38.1% to -$13000.0 in 2022, then dropped by 15.38% to -$15000.0 in 2023, then dropped by 20.0% to -$18000.0 in 2024, then grew by 16.67% to -$15000.0 in 2025.
  • Its Gains from Investment Securities was -$15000.0 in Q3 2025, compared to -$13000.0 in Q2 2025 and -$13000.0 in Q1 2025.